Immunology
Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694
Background: ITK and RLK are unique to effector lymphocytes and critical for immune activation.Results: A novel selective covalent ITK/RLK inhibitor called PRN694 was discovered, which blocks T-cell and NK cell activation.Conclusion: PRN694 provides an effective tool to elucidate the roles of ITK and RLK in immune cell signaling.Significance: PRN694 could be an effective therapy for T-cell- or NK cell-driven autoimmune, inflammatory, and malignant diseases.
